Katsuya Fujimoto
Overview
Explore the profile of Katsuya Fujimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
799
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Izutsu K, Ishikawa T, Shimada K, Kubo K, Kondo T, Fujimoto K, et al.
Int J Hematol
. 2025 Feb;
PMID: 39960615
Zanubrutinib is a selective second-generation Bruton tyrosine kinase inhibitor approved in various B-cell malignancies globally. The phase 1/2 BGB-3111-111 study evaluated the efficacy and safety of zanubrutinib 160 mg twice...
2.
Matsukawa T, Onozawa M, Kondo T, Kanaya M, Hidaka D, Ota S, et al.
Ann Hematol
. 2024 Nov;
103(12):5333-5340.
PMID: 39614924
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with genetic alterations. The FMS-like tyrosine kinase 3 (FLT3) gene is frequently mutated in adult de novo AML, with two types...
3.
Izumiyama K, Inao T, Goto H, Harada S, Senjo H, Suto K, et al.
Haematologica
. 2024 Jun;
109(11):3631-3640.
PMID: 38867578
Information regarding follow-up duration after treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL) is important. However, a clear endpoint has yet to be established. We enrolled a total of...
4.
Miyashita N, Onozawa M, Matsukawa T, Mori A, Hidaka D, Minauchi K, et al.
Br J Haematol
. 2024 Jan;
204(4):1549-1553.
PMID: 38238885
No abstract available.
5.
Kimura H, Onozawa M, Yoshida S, Miyashita N, Yokoyama S, Matsukawa T, et al.
Ann Hematol
. 2023 Aug;
102(11):3103-3113.
PMID: 37597110
IKZF1 deletion is a recurrent genomic alteration in B-cell acute lymphoblastic leukemia (B-ALL) and is divided into dominant-negative (DN) and loss of function (LOF) deletions. The prognostic impact of each...
6.
Miyajima T, Onozawa M, Yoshida S, Miyashita N, Kimura H, Takahashi S, et al.
Eur J Haematol
. 2023 Jul;
111(4):620-627.
PMID: 37465857
Objectives: The cryptic fusion oncogene NUP98::NSD1 is known to be associated with FLT3-ITD mutation in acute myeloid leukemia (AML), and an independent poor prognostic factor in pediatric AML. However, there...
7.
Yokoyama S, Onozawa M, Yoshida S, Miyashita N, Kimura H, Takahashi S, et al.
Br J Haematol
. 2023 Apr;
201(6):1144-1152.
PMID: 37067758
Recent advances in next-generation sequencing (NGS) have enabled the detection of subclinical minute FLT3-ITD. We selected 74 newly diagnosed, cytogenetically normal acute myeloid leukaemia (AML) samples in which FLT3-ITD was...
8.
Miyashita N, Onozawa M, Yoshida S, Kimura H, Takahashi S, Yokoyama S, et al.
Int J Hematol
. 2023 Feb;
118(1):36-46.
PMID: 36853451
Mutation status of FLT3, NPM1, and CEBPA is used to classify the prognosis of acute myeloid leukemia, but its significance in patients with cytogenetically normal (CN) AML is unclear. We...
9.
Yoshida S, Onozawa M, Miyashita N, Kimura H, Takahashi S, Yokoyama S, et al.
Int J Hematol
. 2022 Dec;
117(4):544-552.
PMID: 36572814
Complex karyotype acute myeloid leukemia (CK-AML) has been classified as an adverse-risk subtype. Although a few reports have further classified CK-AML as typical (including monosomy of chromosomes 5, 7 and...
10.
Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, et al.
Support Care Cancer
. 2022 Nov;
30(12):9693-9695.
PMID: 36318340
No abstract available.